{"id":6764,"date":"2023-10-13T21:02:53","date_gmt":"2023-10-14T01:02:53","guid":{"rendered":"https:\/\/lifescivoice.com\/?p=6764"},"modified":"2023-10-13T21:02:55","modified_gmt":"2023-10-14T01:02:55","slug":"15-million-investment-to-compete-in-the-eczema-challenge-alongside-amgen-and-sanofi","status":"publish","type":"post","link":"https:\/\/lifescivoice.com\/15-million-investment-to-compete-in-the-eczema-challenge-alongside-amgen-and-sanofi\/","title":{"rendered":"$15 Million Investment to Compete in the Eczema Challenge alongside Amgen and Sanofi"},"content":{"rendered":"\n<p>Ichnos Sciences has, at last, found a potential buyer for its OX40 eczema venture, as Astria Therapeutics steps forward, offering an initial payment of $15 million and securing a position in the competitive race alongside industry giants Amgen and Sanofi.<\/p>\n\n\n\n<p>Originating from New Jersey, Ichnos has been keen on establishing a partnership for its OX40 initiative ever since its inception. The program was made available for out-licensing just a year after its spin-off from Glenmark in 2019. During the pursuit of a suitable collaborator, Ichnos observed Sanofi&#8217;s acquisition of an OX40 contender through its $1.1 billion acquisition of Kymab, as well as Amgen&#8217;s substantial $400 million upfront payment to Kyowa Kirin to enter the same domain.<\/p>\n\n\n\n<script async=\"\" src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-3812572458252831\" crossorigin=\"anonymous\"><\/script>\n<ins class=\"adsbygoogle\" style=\"display:block; text-align:center;\" data-ad-layout=\"in-article\" data-ad-format=\"fluid\" data-ad-client=\"ca-pub-3812572458252831\" data-ad-slot=\"7669348015\"><\/ins>\n<script>\n     (adsbygoogle = window.adsbygoogle || []).push({});\n<\/script>\n\n\n\n<p>Now, Ichnos has ultimately struck a deal, although not reached the level of financial negotiation achieved by the major pharmaceutical players. The arrangement involves an upfront payment of $15 million, further supplemented by $20 million linked to clinical milestones, and an impressive $285 million earmarked for regulatory and commercial milestones, aligning with Astria&#8217;s specific asset preferences.<\/p>\n\n\n\n<p>Ichnos completed a phase 2 trial for its lead candidate, telazorlimab, targeting OX40, in 2021. However, in Astria&#8217;s official deal announcement, telazorlimab received only minimal recognition. Astria is obtaining licensing rights for the entire OX40 portfolio, placing a strong emphasis on STAR-0310, a preclinical program expected to initiate human trials in early 2025.<\/p>\n\n\n\n<p>Nevertheless, this schedule positions Astria years behind the industry leaders. Amgen has already commenced seven phase 3 clinical trials for its rocatinlimab candidate within the past 16 months, whereas Sanofi disclosed positive phase 2b outcomes in June.In contrast, clinical results for STAR-0310 in healthy volunteers are unlikely to be available until the third quarter of 2025. By that point, Amgen might have already acquired phase 3 data for rocatinlimab.<\/p>\n\n\n\n<p>Astria&#8217;s deliberate choice to emphasize a preclinical program, instead of advancing telazorlimab into late-stage studies, could potentially grant them a distinct candidate status. The biotech perceives STAR-0310 as a leading prospect, highlighting its integration of half-life extension technology, likely reducing dosing frequency. Early indications of superior affinity, safety, and tolerability serve to reinforce their case.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ichnos Sciences has, at last, found a potential buyer for its OX40 eczema venture, as Astria Therapeutics steps forward, offering an initial payment of $15 million and securing a position in the competitive race alongside industry giants Amgen and Sanofi. Originating from New Jersey, Ichnos has been keen on establishing a partnership for its OX40 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":6765,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[],"class_list":{"0":"post-6764","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-commercial"},"_links":{"self":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/6764","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/comments?post=6764"}],"version-history":[{"count":1,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/6764\/revisions"}],"predecessor-version":[{"id":6766,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/6764\/revisions\/6766"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/media\/6765"}],"wp:attachment":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/media?parent=6764"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/categories?post=6764"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/tags?post=6764"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}